linjc16/ctgov huggingface dataset:
Influence of Gravity on Dexterity, Hand-eye Coordination and Perception of Orientation and Distances

Study Overview
=================
Brief Summary
-----------------
If investigators know that the anticipatory mechanisms involved in precision grip take into account the gravity, however it is unclear how they adapt to changes in the gravitational level. The objectives of this study are to study and model the movement control and the mechanisms underlying learning and adapting to the condition of weightlessness. Specifically, i) investigators will determine if a change in the level of gravity is taken into account when controlling grip force and ii) investigators will examine the effects of gravity change on hand-eye coordination.

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Other: Parabolic flight
* Other: movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers, male or female 18 to 65 years Affiliated with a Social Security plan or holder of a European Health Insurance Card (EHIC - European Health Insurance Card - EHIC). Having an aeronautical medical certificate of fitness for flight personnel unprofessional functions in civil aviation. Agreeing to participate in the study Having given informed consent Exclusion Criteria: person not affiliated to a Social Security Inssurance, person who participated in a clinical trial within the trial below the exclusion period, person with a medical history or any acute or chronic condition that can affect the test results, or by running a risk on during the protocol, especially topics: past or present history of neurological disease, rheumatologic or otologic (hearing or equilibration) OR person with a corrected visual acuity of less than 5 / 10th. pregnant women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Dexterity, Coordination,Perception measurements<br>Dexterity, Hand-eye Coordination and Perception of Orientation and Distances | Other: Parabolic flight<br> <br> Other: movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gravity induced changes in grip strength (newton) exerted between the fingers measured with strain gauges |  | baseline | 
| Gravity induced changes in oculo-manual coordination measured by the latency (ms) of anticipatory eye movement measurement with videooculography |  | baseline |
The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

Study Overview
=================
Brief Summary
-----------------
PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms.

Official Title
-----------------
Clinical Usefulness of Proton Pump Inhibitor Test for Identifying Gastroesophageal Reflux Disease in Patients With Extraesophageal Symptoms

Conditions
-----------------
Gastroesophageal Reflux Disease

Intervention / Treatment
-----------------
* Drug: Proton pump inhibitor (rabeprazole)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with extraesophageal manifestation symptoms of GERD Exclusion Criteria: laryngeal, pharyngeal, liver, lung, renal, or hematological disorders a history of gastrointestinal surgery, and a history of connective tissue disorders. patients with duodenal or gastric ulcers as well as other significant lesions, such as gastric cancer, esophageal cancer, or subepithelial tumors more than 1 cm observed on the upper endoscopy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom responders after PPI trials |  | 2 weeks after PPI trials | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients with extraesophageal manifestation of gastroesophageal reflux disease
Treatment of Polydrug-Using Opiate Dependents During Withdrawal

Study Overview
=================
Brief Summary
-----------------
Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for long-term treatment. In our clinical practice we have felt the need for a standardised and safe detoxification treatment regimen for our opioid addicts, as dependence on multiple drugs is so common. Objectives To assess whether a novel standardised treatment regimen - Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate-polydrug users than the existing treatment regimen, i.e. Clonidine (CLN) combined with Carbamazepine (CBZ). To determine whether there are differences in treatment retention between the BPN/VPA and the CLN/CBZ groups. To assess differences in clinical side-effects and biochemical interactions between the two treatment regimens.

Official Title
-----------------
Treatment of Polydrug-Using Opiate Dependents During Withdrawal

Conditions
-----------------
Opiate Dependence, Drug Dependence, Substance Withdrawal Syndrome

Intervention / Treatment
-----------------
* Drug: Buprenorphine
* Drug: Valproate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Polydrug dependency (at least opiate and benzodiazepine dependency) Exclusion Criteria: No severe psychiatric illness No history of epilepsy seizures No pregnancy or breastfeeding Fertile women must use contraceptives

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|
|Drug: Valproate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retention in treatment |  |  | 
| Withdrawal symptoms |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum concentration of Valproate and Buprenorphine separately and in combination |  |  | 
| Urine testing |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Opiate dependence, Benzodiazepine dependence, Polydrug Abuse, Detoxification, Withdrawal Treatment
Metabolomic Alterations in the Vascular Compartment in Patients With Sepsis

Study Overview
=================
Brief Summary
-----------------
This study will investigate the metabolic alterations of vascular cells caused by sepsis and septic shock

Detailed Description
-----------------
This study will investigate the metabolic alterations of vascular cells caused by sepsis and septic shock in 60 patients

Official Title
-----------------
Metabolomic Alterations in the Vascular Compartment in Patients With Sepsis - an Observational Study

Conditions
-----------------
Endothelial Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 year or older Sepsis or Septic shock Exclusion Criteria: Pregnant or breastfeeding Hemoglobin ≤ 5.0 mmol/L Platelets ≤ 5.0 mia/L Consent not obtainable Do not resuscitate order

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Shock induced endotheliopaty | Mortality | Up to 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sepsis, systems biology, metabolomics
The Influence of Plaquenil/Hydroxychloroquine (HCQ) on Insulin Secretion

Study Overview
=================
Brief Summary
-----------------
Antimalarials such as hydroxychloroquine (HCQ), are among the oldest prescribed drugs still used in clinical practice. Relatively inexpensive and well tolerated, these drugs have been recognized to be effective in autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Interestingly, there is growing evidence of their beneficial impact on cardiovascular risk, particularly diabetes. HCQ therapy can improve balance in patients with unbalanced diabetes. This drug therapy may be a new therapeutic approach for diabetes. There is need for a better understanding of the mechanisms responsible for the improvement of the metabolic response to drug treatment. The investigators hypothesize that treatment with a drug improves the function of the beta cell and its ability to secrete insulin in response to glucose. The investigators will examine the impact of short-term therapy for HCQ in beta cell function in healthy volunteers and in patients with type 2 diabetes.

Conditions
-----------------
Diabetes Type Two

Intervention / Treatment
-----------------
* Drug: Hydroxychloroquine


Participation Criteria
=================
Eligibility Criteria
-----------------
Two groups will participate in this study: Healthy volunteers and Diabetes patients A. Healthy volunteers Inclusion Criteria: Age: 18-40 Without acute disease at the day of the experiment. Signed informed consent Exclusion Criteria: Malignancy Steroids or NSAID on a daily basis B. Diabetes patients Inclusion Criteria: Age: 20-60 Diabetes type two Untreated or on metformin treatment Exclusion Criteria: Hypoglycemic medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy volunteers<br> | Drug: Hydroxychloroquine<br>* 200 MG Plaquenil three times a day<br>* Other names: Plaquenil;|
| Experimental: Diabetes patients<br> | Drug: Hydroxychloroquine<br>* 200 MG Plaquenil three times a day<br>* Other names: Plaquenil;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glucose level |  | the change in glucose level between baseline and after three hours |
A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay

Study Overview
=================
Brief Summary
-----------------
The ARIES Norovirus Assay is a real-time PCR based qualitative in vitro diagnostic test for the direct detection of Norovirus GI/GII RNA from stool specimens obtained from symptomatic patients. The purpose of this study is to establish the diagnostic accuracy of ARIES Norovirus Assay.

Detailed Description
-----------------
The ARIES Norovirus Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection of Norovirus GI/GII RNA from stool specimens obtained from symptomatic patients. The objective is to establish the diagnostic accuracy of the ARIES Norovirus assay through a multi-site, method comparison on prospectively collected leftover, stool specimens. Diagnostic accuracy will be expressed in terms of clinical sensitivity (or positive agreement) and specificity (or negative agreement)

Official Title
-----------------
A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay in Patients With Signs and Symptoms of Acute Gastroenteritis

Conditions
-----------------
Acute Gastroenteritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The specimen is from a patient with symptoms of acute gastroenteritis. The specimen is from a male or female subject who was either hospitalized, admitted to a hospital emergency department or visiting an outpatient clinic. The subject's specimen is an unpreserved, unformed (liquid or soft) stool submitted for testing at the site. Exclusion Criteria: The specimen is from an individual with known and documented non-infectious conditions such as ulcerative colitis, irritable bowel syndrome and/or Crohn's disease The specimen was not properly collected, transported, processed or stored according to the instructions provided by the sponsor.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy will be expressed in terms of clinical sensitivity (or positive agreement) and specificity (or negative agreement). | Accuracy determinations (diagnostic sensitivity and specificity, positive and negative agreement) were based on the fraction of comparator positive (or negative) results which were also positive (or negative) by ARIES Norovirus Assay. | Within the first year of sample collection |
Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer

Study Overview
=================
Brief Summary
-----------------
All the preoperative biopsies of patients suffering colorectal cancer (CRC) will be immunohistochemically stained with a pancytokeratin marker to detect Tumor buds. then, the intratumoral buds (ITB) in the densest Region of Tumor buds, namely the hot spot will be counted. Subsequently, the probability of N stage (lymphnodes), M stage (metastases) and disease free survival (DFS) will be calculated based on an existing logistic Regression model already developed by our previous retrospective work. Additionally, a Standardisation of ITB using a well- established Software will develop an algorithm which will help to eliminate inter- observer variability of Tumor budding Counts.

Official Title
-----------------
Assessment of Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer Patients: a Prospective Observational Study

Conditions
-----------------
CRC

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with newly diagnosed stages I and IV colorectal cancer (CRC) Age ≥ 18 years Written Informed Consent Exclusion Criteria: No consent < 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation of ITB based calculated N stage with real N stage in CRC - patients |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation of ITB based calculated DFS with real DFS in CRC - patients |  | 24 months |
Mobile Education for Emergency Ultrasound

Study Overview
=================
Brief Summary
-----------------
The investigators aim to investigate the feasibility of using mobile application platform for sonographic education. Junior physicians at the National Taiwan University Hospital will be enrolled in this study. To design and develop a secure mobile application platform (consisting of mobile device and a cloud-based server) for interactive teaching, remote social-based consultation and discussion. The information exchange through the platform carries images and simulated cases. This pioneer study can provide experience of mobile sonographic education and contribute to current medical education. Moreover, it can improve decision-making process and quality of care, and could lessen crowdedness at emergency departments. Furthermore, the integrated platform can be used in other educational programs in the future.

Detailed Description
-----------------
As usual, it takes time for junior emergency physicians to have good diagnostic accuracy through traditional sonographic education. Applying the technology built in this project, junior emergency physicians will be provided with intelligent learning programs anywhere and anytime. Junior physicians at the National Taiwan University Hospital will be enrolled in this study.

Official Title
-----------------
Mobile Education for Emergency Ultrasound

Conditions
-----------------
Educational Problems

Intervention / Treatment
-----------------
* Other: educational platform


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: The junior physicians of the department of emergency medicine of the National Taiwan University Hospital. Exclusion criteria: The junior physicians of the department of emergency medicine of the National Taiwan University Hospital, refused to enter the study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| use of the educational platform<br>Before the hand-on practice and assessements, the participants use the platform for learning. | Other: educational platform<br>* The platform would be opened before they entered the study.<br>|
| without use of the educational platform<br>Before the hand-on practice and assessements, the participants did not use the platform for learning. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assessment for ultrasound scanning | use 5-point Likert scale (1 to 5 scores) | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
emergency medicine ,emergency ultrasound
A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to compare how accurately the Xpert MTB/RIF assay Ct value at diagnosis and the AI-based tuberculosis activity score predict the treatment outcome of rifampin-susceptible pulmonary tuberculosis patients. As a retrospective observational study, data from patients diagnosed with rifampin susceptible pulmonary tuberculosis through the Xpert MTB/RIF assay performed on sputum in 2019 at the participating institutions will be analyzed (up to 900 people).

Official Title
-----------------
A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress

Conditions
-----------------
Pulmonary Tuberculoses, Tuberculosis, Pulmonary

Intervention / Treatment
-----------------
* Other: Medical records review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with rifampin-susceptible pulmonary tuberculosis by Xpert MTB/RIF assay with sputum samples between January 1, 2019 and December 31, 2019 Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Medical records review|The clinical characteristics at the time of diagnosis of rifampin-susceptible pulmonary tuberculosis patients, the Xpert MTB/RIF assay Ct value, the tuberculosis activity score based on AI of the chest image, and treatment results will be collected retrospectively through medical records.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Negative culture conversion until 8 weeks after initiation of treatment | Conversion from positive tuberculosis culture to negative tuberculosis culture | Within 8 weeks of initiating treatment | 
| Time to negative culture conversion | Time (days) to conversion from positive tuberculosis culture to negative tuberculosis culture | Within 6 months of initiating treatment | 
| Treatment outcome including 1) Cure 2) Treatment completion 3) Treatment failure 4) Death 5) Loss of follow-up 6) Unknown | Cure: confirmed negative culture conversion plus negative culture results from at least one sputum on the month of treatment completion Treatment completion: confirmed negative culture conversion at least once during treatment Treatment failure: positive culture results after 4 months of treatment Death: death during treatment Loss of follow-up: loss of follow-up during treatment Unknown | Within 2 years of initiating treatment |